Clinical trial
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
NCT06039683 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 31, 2022
- Completion date
- July 4, 2024
- Enrollment
- 54 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.